SSA
ELDN icon

Schonfeld Strategic Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-998,454
Closed -$2.71M – 2299
2025
Q2 		$2.71M Sell
998,454
-320,388
-24% -$961K 0.02% 822
2025
Q1 		$4.47M Sell
1,318,842
-196,908
-13% -$810K 0.03% 563
2024
Q4 		$6.24M Buy
1,515,750
+15,750
+1% +$62.1K 0.04% 428
2024
Q3 		$3.73M Hold
1,500,000
– – 0.02% 638
2024
Q2 		$3.96M Buy
1,500,000
+1,449,200
+2,853% +$3.46M 0.03% 634
2024
Q1 		$105K Buy
+50,800
New +$90.7K ﹤0.01% 1845

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Schonfeld Strategic Advisors's ELDN Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 998,454 shares — an estimated $2.71M sold.

Schonfeld Strategic Advisors first reported a position in ELDN in Q1 2024 and held it in 6 quarters. The position peaked at $6.24M in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 998,454 Eledon Pharmaceuticals shares in Q3 2025, an estimated $2.71M.
  • Schonfeld Strategic Advisors first reported a position in Eledon Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's Eledon Pharmaceuticals position peaked at $6.24M in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.